PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.05
Positive D/E while AGEN shows negative equity. John Neff would examine our competitive advantages in a challenging market.
9.77
Net debt while AGEN maintains net cash position. John Neff would demand higher returns to justify the additional leverage risk.
No Data
No Data available this quarter, please select a different quarter.
9.14
Current ratio exceeding 1.5x AGEN's 0.21. Charlie Munger would verify if this advantage translates to better supplier terms.
No Data
No Data available this quarter, please select a different quarter.